Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a paper he co-authored published on ESMO Open on LinkedIn:
“Published in ESMO Open!
Thrilled to share our new study, which I had the privilege to lead with Josep Tabernero MD, PhD at SOLTI.
Special shout-out: Elia Seguí, MD, first co-author, did an outstanding job assembling the datasets, running many of the key analyses, and drafting the manuscript.
Thank you, Elia!
‘Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohorts 1–2 of the phase II SOLTI-1904 ACROPOLI trial.’
What we did: Prospective, basket-type evaluation of PD1 mRNA as a pan-cancer biomarker for anti-PD1 therapy.
Key results (n prescreened = 1,003 across 33 cancers):
- PD1-high prevalence: 10.6%.
- Objective response rate (ORR) in PD1-high: 17.9% overall; 33.3% when using recent tissue (≤12 months).
- Responses seen even in typically ICI-resistant tumors (e.g., pancreatic, MSS colorectal).
- Composite biology matters: PD-L1 CPS associated with response; DNADX DNA copy-number–based features (a proliferative cluster-4 and low B-cell signature) independently linked to higher ORR, supporting integration of protein + DNA + mRNA markers for smarter selection.
Despite early closure of cohorts 1–2 (sponsor stopped spartalizumab development), these findings provide prospective evidence that PD1 mRNA, especially with fresh tissue, can help flag immunogenic tumors beyond the usual suspects.
Cohort 3 with tislelizumab is ongoing.
Grateful to all co-authors, participating centers, and – above all – the patients and families.”
Title: Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
Authors: E. Seguí, F. Brasó-Maristany, T. Pascual, E. Sanfeliu, I. Victoria, C. Saura, C. Hierro, A. López-González, Y. Izarzugaza, E. Ciruelos, J. Gavilá, F. Racca, J.M. Cejalvo, K. Amillano, L. Paz-Ares, M. Juan, E. Felip, E. Garralda, B. González, A. Arance, J. Martín-Liberal, B. Conte, B. Walbaum, A. Indacochea, O. Castillo, P. Blasco, F. Pardo, Á. Aguirre, V. Sirenko, X. González, P. Galván, A. Vivancos, J.M. Ferrero-Cafiero, A. Mulero-Sánchez, F. Salvador, G. Villacampa, R. Mesía, A. Cervantes, A. Prat, J. Tabernero
Read the full article on ESMO Open.
Read more posts featuring Aleix Prat on OncoDaily.